This market study concludes with profiles of key players in the global postpartum hemorrhage treatment devices market. The report summarizes the companies in terms of overview, financial overview, product portfolio, business strategies, and recent developments.

Albany, NY -- (SBWire) -- 01/20/2016 --Postpartum devices have been available in the market for more than two decades, however awareness about these solutions is exceptionally low in less developed and developing regions such as the Middle East, sub-Saharan Africa, and Asia Pacific. In countries such as Bangladesh, Nepal, Bhutan and parts of Africa, approximately 55% to 65% of births occur in homes; of these, a significant proportion of pregnant women face postpartum hemorrhage. In Africa and Asia, where most maternal deaths occur, PPH accounts for more than 30% of all maternal deaths. The WHO defines primary postpartum hemorrhage as the excess blood loss that is greater than or equal to 500 ml occurring within 24 hours after child delivery; whereas secondary PPH occurs from 24 hours to 12 weeks. Several public health surveys have shown that over two-thirds of the maternal deaths are attributable to obstetric hemorrhage and the incidence of major obstetric hemorrhage (such as postpartum hemorrhage) is increasing significantly in developed as well as developing countries.

Complete Report with TOC @ http://www.mrrse.com/postpartum-hemorrhage-treatment-devices-market

PPH is generally caused by four major medical conditions, commonly referred as the "four Ts or 4 Ts" mnemonic: tone (uterine atony), trauma, tissue (retained placenta), and thrombin (coagulopathy). Uterine atony is the most common cause of PPH, accounting for almost 75% to 80% of primary PPH cases. Scientific data based on high quality evidence suggest that active management of the third stage of labor reduces the severity and incidence of PPH. Active management generally includes immediate administration of uterotonic agents (e.g. oxytocin, prostaglandins, and ergot alkaloids) post-delivery, early cutting and clamping of umbilical cord, and gentle traction to the umbilical cord.

Based on product classification, the postpartum hemorrhage treatment devices market has been segmented into no-pneumatic anti-shock garment (NASG), Uniject prefilled injection system, and uterine balloon tamponades. The uterine balloon tamponade segment has been categorized into Foley catheters, condom catheters, and others. Uterine balloon tamponades accounted for the largest market share in 2014. Factors such as ultra-low cost, easy availability, and high effectiveness have been attributed to the largest share of the uterine balloon tamponades segment. However, Uniject prefilled injection system is expected to grow at the fastest CAGR of over 5% during the forecast period due to factors such as increasing involvement of governmental organizations, easy applicability, equitable pricing, and growing product adoption.

Geographically, North America accounted for the largest share of the global postpartum hemorrhage treatment devices market in 2014. Factors such as rise in maternal mortality due to PPH, improved access to health care, convenient availability of medical devices, and rising incidence of obstetric complications are driving the postpartum treatment devices market in North America. However, Asia Pacific is anticipated to witness the highest growth during the forecast period. Fastest growth rate in this region is anticipated to emerge due to high prevalence of PPH and other pregnancy related obstetrics complications, growing awareness among health care providers, and improving healthcare infrastructure. In addition, prevalence of anemia among women in developing countries such as India, China, and Hong Kong is high (over 60%); this complicates the cases of patients experiencing PPH. Furthermore, currently, around 65% of the deliveries in developing countries are managed by skilled health care personnel in order to reduce the risk of PPH. Thus, these factors are cumulatively expected to drive the PPH treatment devices market in the region.

Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/360

The global postpartum hemorrhage treatment devices market is highly competitive due to the presence of many global as well as regional players. The prominent companies operating in the postpartum hemorrhage treatment devices market includes Cook Medical, Inc., Teleflex Incorporated, C. R. Bard, Inc., 3rd Stone Design, Inc., Bactiguard AB, Program for Appropriate Technology in Health (PATH), Utah Medical Products, Inc., and ZOEX NIASG.

About MRRSE
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.